title: Pulmonary lymphoma in cardiac transplant patients treated with OKT3 for rejection: diagnosis by fine-needle aspiration.
abstract: At Hines VA Hospital, three out of 38 cardiac transplant patients, who were 9, 10, and 14 mo post-surgery and treated with immunosuppressive drugs, including OKT3 prophylaxis for acute rejection, developed a solitary pulmonary nodule. Fine-needle aspiration biopsy of the nodules in these three patients revealed a hypercellular, monotonous population of large lymphoid cells. These abnormal cells were isolated, with small aggregates occasionally seen. The nuclear membranes were irregular, the chromatin was finely granular, nucleoli were prominent, and mitotic figures were frequently noted. The cells were immunoreactive to leukocyte common antigen and B-lymphocyte. Lambda light chain immunoglobulin was positive in one case, kappa in the second case, and neither light chains in the third patient. By electron microscopy in one case, the cells were large immature lymphoid cells with immunoblastic features. Subsequent tissue studies, complemented by frozen section immunostaining, flow cytometry, and phenotyping, reaffirmed the diagnosis of malignant lymphoma. It appears that OKT3 therapy increases several fold the risk of lymphoma's developing in cardiac transplant patients. Preliminary published reports have also recommended close surveillance of patients receiving OKT3 for early indications of lymphoproliferative disorder and a reevaluation of the risk vs. benefit for the prophylatic use of OKT3.
authors.affiliation: Cytology Section, Veterans Affairs Hospital, Hines, IL, USA.
authors.forename: C V
authors.initials: CV
authors.lastname: Reyes
authors.forename: J A
authors.initials: JA
authors.lastname: Jensen
authors.forename: M
authors.initials: M
authors.lastname: Chinoy
mesh_terms: D000328:Adult; D001707:Biopsy, Needle; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced / Q000473:pathology*; D008223:Lymphoma / Q000139:chemically induced / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D016853:Muromonab-CD3